Addison Advisors LLC Sells 385 Shares of Merck & Co., Inc. (NYSE:MRK)

Addison Advisors LLC lowered its position in Merck & Co., Inc. (NYSE:MRK) by 6.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,861 shares of the company’s stock after selling 385 shares during the period. Addison Advisors LLC’s holdings in Merck & Co., Inc. were worth $666,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Itau Unibanco Holding S.A. purchased a new stake in shares of Merck & Co., Inc. during the 2nd quarter valued at about $39,000. Abich Financial Wealth Management LLC grew its position in Merck & Co., Inc. by 121.8% during the second quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock valued at $40,000 after buying an additional 179 shares during the period. Quarry LP purchased a new stake in Merck & Co., Inc. during the second quarter valued at approximately $42,000. Strategic Financial Concepts LLC increased its holdings in Merck & Co., Inc. by 1,475.6% during the second quarter. Strategic Financial Concepts LLC now owns 35,057 shares of the company’s stock valued at $43,000 after buying an additional 32,832 shares during the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC raised its position in Merck & Co., Inc. by 47.5% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 379 shares of the company’s stock worth $43,000 after acquiring an additional 122 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Up 1.7 %

Shares of MRK opened at $102.92 on Monday. Merck & Co., Inc. has a twelve month low of $98.60 and a twelve month high of $134.63. The company has a current ratio of 1.36, a quick ratio of 1.22 and a debt-to-equity ratio of 0.79. The company’s fifty day simple moving average is $110.74 and its 200-day simple moving average is $119.94. The company has a market cap of $260.35 billion, a P/E ratio of 21.58, a P/E/G ratio of 1.47 and a beta of 0.40.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Thursday, October 31st. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.07. The business had revenue of $16.66 billion during the quarter, compared to the consensus estimate of $16.47 billion. Merck & Co., Inc. had a return on equity of 36.42% and a net margin of 19.23%. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period last year, the company earned $2.13 earnings per share. As a group, analysts expect that Merck & Co., Inc. will post 7.75 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on MRK shares. UBS Group reduced their price objective on Merck & Co., Inc. from $142.00 to $136.00 and set a “buy” rating for the company in a research note on Wednesday, October 9th. Wolfe Research upgraded Merck & Co., Inc. to a “strong-buy” rating in a research note on Wednesday, July 31st. Daiwa Capital Markets cut shares of Merck & Co., Inc. from a “buy” rating to a “neutral” rating in a research note on Monday. Sanford C. Bernstein initiated coverage on shares of Merck & Co., Inc. in a report on Thursday, October 17th. They set a “market perform” rating and a $115.00 price target on the stock. Finally, Bank of America decreased their price objective on shares of Merck & Co., Inc. from $150.00 to $145.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have given a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $130.86.

Merck & Co., Inc. Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.